Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.

A, Blauvelt; CL, Leonardi; M, Gooderham; KA, Papp; S, Philipp; JJ, Wu; A, Igarashi; M, Flack; Z, Geng; T, Wu; A, Camez; D, Williams; RG, Langley

doi:10.1001/jamadermatol.2020.0723

Public

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.

Shared by NobleBlocks on Jun 1, 2020 • 12:00 AM UTC

Authors:

Blauvelt A

Leonardi CL

Gooderham M

Abstract

<h4>Importance</h4>Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to psoriatic inflammation.<h4>Objective</h4>To evaluate the efficacy and safety of risankizumab vs placebo and continuous treatment vs withdrawal in adults with moderate to severe plaque psoriasis.<h4>De...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!